Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on developing gene therapy solutions for common eye diseases, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on developing gene therapy solutions for common eye diseases, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's presentation is scheduled for Tuesday, February 11, at 4:40 p.m. ET.
Interested parties can access the presentation webcast through the Events and Presentations section in the Investors area of Adverum's website. The presentation recording will remain available for viewing on the company's website for a minimum of 30 days after the event.
Details
News Market Reaction – ADVM
The recorded move for ADVM in the trading session of this news was -4.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, at 4:40 p.m. ET.
The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for at least 30 days following the event.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.